3319 results about "Dopamine" patented technology

A sensor is disclosed, for implantation within a blood vessel to monitor a substance in or property of blood. In one embodiment, the sensor detects nitric oxide or a nitric oxide metabolite. In another embodiment, other substances such as glutamate, aspartate, arginine, citrulline, acetylcholine, calcium, potassium, or dopamine are monitored. The sensor may be attached to a support structure such as a stent, guidewire, or catheter. In a further embodiment, a catheter is disclosed that extracts patient fluid to a sensor outside the body for monitoring a substance or property of the patient fluid. Methods are also disclosed.

In Pavlovian and instrumental conditioning, rewards typically come seconds after reward-triggering actions, creating an explanatory conundrum known as the distal reward problem or the credit assignment problem. How does the brain know what firing patterns of what neurons are responsible for the reward if (1) the firing patterns are no longer there when the reward arrives and (2) most neurons and synapses are active during the waiting period to the reward? A model network and computer simulation of cortical spiking neurons with spike-timing-dependent plasticity (STDP) modulated by dopamine (DA) is disclosed to answer this question. STDP is triggered by nearly-coincident firing patterns of a presynaptic neuron and a postsynaptic neuron on a millisecond time scale, with slow kinetics of subsequent synaptic plasticity being sensitive to changes in the extracellular dopamine DA concentration during the critical period of a few seconds after the nearly-coincident firing patterns. Random neuronal firings during the waiting period leading to the reward do not affect STDP, and hence make the neural network insensitive to this ongoing random firing activity. The importance of precise firing patterns in brain dynamics and the use of a global diffusive reinforcement signal in the form of extracellular dopamine DA can selectively influence the right synapses at the right time.

The present invention provides compositions, methods, and kits for treatment of Parkinson's disease and other conditions for which treatment with a dopamine agonist is therapeutically beneficial. The invention provides a biocompatible nonerodible polymeric device which releases dopamine agonist continuously with generally linear release kinetics for extended periods of time. Dopamine agonist is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with dopamine agonist.

This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics.

This invention relates to a galenical gel formulation for nasal administration of neurotransmitters/neuromodulators such as dopamine, serotonin or pregnenolone and progesterone. The special lipophilic or partly lipophilic system of the invention leads to high bioavailability of the active ingredient in plasma and brain caused by sustained serum levels and/or direct or partly direct transport from nose to the brain.

The invention discloses a polydopamine-based biofunction modification method. The method comprises the following steps of: soaking clean inorganic/metal materials in dopamine alkaline aqueous solution with a pH value of 7.2 to 10, introducing oxygen to fully oxidize the clean inorganic/metal materials to obtain a monolayer polydopamine modification layer, drying, placing the material in the air atmosphere at 50 to 200 DEG C, performing thermal oxidation to obtain a multi-layer firmly-combined high-reactivity polydopamine layer, and soaking the treated material into the amino-containing and sulfydryl-containing biofunctional molecular solution to obtain a firmly combined biofunction simulate modification layer on the surface of the materials. The polydopamine modification layer obtained bythe method has excellent anti-deformation performance, stability and reactivity, can directly react with amino or the sulfydryl in the biomolecule to immobilize the bioactive molecule on the surface by covalent bonds; moreover, the process is simple, the condition is mild, and the method is easy to implement.

The invention discloses a preparation method of a hydrophilic antimicrobial film of which the surface is coated with dopamine and polyethyleneimine cations. The preparation method comprises the following steps that a base film is prepared, the base film is immersed in a dopamine solution, a polydopamine layer is formed on the surface of the base film by dopamine auto-agglutination, and the polydopamine layer and a polyethyleneimine aqueous solution undergo a reaction so that the hydrophilic antimicrobial film is prepared by the cationization reaction. The preparation method is simple and easy and has mild reaction conditions. The prepared hydrophilic antimicrobial film has excellent hydrophilicity and antibacterial properties, reduces adherence of microbes such as organic matters and bacteria, has a bacterium killing capability and prolongs a film service life.

The invention relates to a method for preparing a high-flux composite membrane from a dopamine-modified nanometer material and belongs to the technical field of modification of membrane materials. The method is characterized by comprising the following steps of: forming an active poly-dopamine composite layer on the surfaces of titanium dioxide nanometer grains by utilizing automatic polymerization of dopamine, selecting different concentrations of dopamine-modified titanium dioxide grains, and adding the modified nanometer grains utilized as additives into a membrane casting solution, in which the mass fraction of PVDF (Polyvinylidene Fluoride) is 13% and the mass fraction of PVP (Polyvinyl Pyrrolidone) is 4%, so as to bend and modify according to different proportions, thus obtaining a composite membrane prepared from dopamine-modified nanometer titanium dioxide. The method for preparing the high-flux composite membrane from the dopamine-modified nanometer material, disclosed by the invention, has the advantages that dopamine-modified titanium dioxide can be greatly dispersed in an organic solvent to form a uniform dispersed phase; the additive can be used for effectively improving the hydrophilcity and anti-pollution capability of the high-flux composite membrane; and the dopamine modification method is simple, the condition is gentle, the flux of the prepared membrane is large and the anti-pollution capability is strong.

This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents_useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics.

Disclosed herein is a method for protecting dopaminergic neurons of a mammal against death resulting from Parkinson's disease. The method comprises administering a neuroprotective amount of the tripeptide Gly-Pro-Glu.

The present invention relates to methods for treating or preventing symptoms of hormonal variation. The method comprises the steps of administering an effective amount of a receptor antagonist to a subject having one or more symptoms of hormonal variations, wherein the receptor antagonist binds to at least one receptor selected from the group consisting of a serotonin type 2A (5-HT_2A) and a dopamine type 2 (D₂) receptors.

The invention relates to a pharmaceutical composition for administering the dopamine agonist N-0923 in depot form. The invention makes available for the first time a depot form of N-0923, which achieves a therapeutically significant plasma level over a period of at least 24 hours after administration to a patient. As a result of poor oral bio-availability and the short plasma half-life, N-0923 was previously administered either by an intravenous drip or by transdermal systems. Preferred embodiments of said invention are oily suspensions, containing the active ingredient N-0923 in a solid phase, in addition to anhydrous pharmaceutical preparations of N-0923.

A method for the treatment of Restless Leg Syndrome (RLS), which comprises administering an alpha2-agonist and a second agent selected from the group consisting of the dopamine agonists, opioids, benzodiazepines and the combination of L-DOPA plus a decarboxylase inhibitor.

The pharmaceutical composition of the present invention comprises a carbostyril derivative which is a dopamine-sero-tonin system stabilizer and a mood stabilizer in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof. The mood stabilizer may include but is not limited to lithium, valproic acid, divalproex sodium, carbamaza-pine, oxcarbamazapine, zonisamide, lamotragine, topiramate, gabapentin, levetiracetam or clonazepam. These compositions are used to treat patients with mood disorders, particularly bipolar disorder with or without psychotic features, mania or mixed episodes. Methods are provided for separate administration of a carbostyril derivative and a mood stabilizer to a patient with a mood disorder.

The invention discloses poly dopamine-modified reduced graphene oxide and a preparation method and application thereof, the polydopamine-modified reduced graphene oxide includes reduced graphene oxide and poly dopamine, and the poly dopamine is attached to the surface of the reduced graphene oxide in physical adsorption manner. The preparation method comprises the following steps: according to the mass ratio of (1-4): (1-4), weighing graphene oxide and dopamine hydrochloride, adding the graphene oxide and the dopamine hydrochloride into solvent to completely dissolve to prepare a mixed solution; adjusting the pH value of the mixed solution to 8.5-9, and reacting for 12h-24h at the temperature of 55 to 65 DEG C to obtain the poly dopamine-modified reduced graphene oxide. The preparation method is friendly to the environment, low in reduction temperature, in no need of adding a stabilizer, and simple in process, realizes the reduction and stabilization in one step, and is suitable for mass production. The invention also provides the application of the poly dopamine-modified reduced graphene oxide.

There is provided a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of a Notch gene. Specifically, the invention provides a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells in vitro, which method comprises introducing a Notch gene and/or a Notch signaling related gene into the cells, wherein the finally obtained differentiated cells are the result of cell division of the bone marrow stromal cells into which the Notch gene and/or Notch signaling related gene have been introduced. The invention also provides a method of inducing further differentiation of the differentiation-induced neural cells to dopaminergic neurons or acetylcholinergic neurons. The invention yet further provides a treatment method for neurodegenerative and skeletal muscle degenerative diseases which employs neural precursor cells, neural cells or skeletal muscle cells produced by the method of the invention.

The present invention is directed to the use of ibudilast for treating addictions, including drug and behavioral addictions. In particular, ibudilast is used to diminish the dopamine-mediated reward associated with addictions and to treat withdrawal syndromes after discontinuance of addictive drug use or behavior.

The invention discloses a method for conducting surface chemical copper plating on inorganic particles through dopamine. The method comprises the steps that poly-dopamine layers are made to subside on the surfaces of the inorganic particles in an alkaline solution through the oxidative polymerization effect of the dopamine, then by utilizing functional groups of the poly-dopamine layers, and meanwhile under the effect of an additional auxiliary reducing agent of dimethylamine broane (DMAB), copper ions are reduced to pure copper on the surfaces of the inorganic particles, and a continuous and compact metal copper layer is formed. The method is simple to operate, low in equipment requirement and low in cost; the prepared copper-plated inorganic particles have the characteristics of being low in density, good in conductivity and the like; the method can be used for preparing electricity and thermal conductive coatings, electromagnetic shielding paint, wave-absorbing materials and the like.

The invention discloses a polysaccharide-dopamine composite biogel and application of the biogel. A preparation method of the biogel comprises the following steps: dissolving 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and N-hydroxy succinimide sodium in an MES (Methyl Ester Sulfonate) buffer solution with a pH value being 5-6 in an inert gas atmosphere so as to prepare an EDC (ethylcarbodiimide) mixed solution, subsequently adding the EDC mixed solution into a polysaccharide solution for reacting at 20-30 DEG C for 0.5-1 hour, then adding a dopamine solution for further reacting at 20-30 DEG C for 1-4 hours, dialyzing a reactant by taking distilled water as a dialyzate, taking trapped fluid for freezing and drying to obtain the polysaccharide-dopamine composite biogel. The polysaccharide-dopamine composite biogel is simple and effective in modification method and capable of increasing the surface viscidity of the cartilage tissue, reducing loss of therapeutic drugs or implanted cells and facilitating the repairing of the cartilage injury.